Johnson & Johnson (JNJ) is expected to report Q2 earnings on Tuesday, July 19 before the market open with a conference call scheduled for 8:30 am...

Posted on 05/02/11 at 7:14am by Benzinga Staff . Citi raised its 2011E EPS from $3.68 to $3.74 vs. the Street's $3.69 & MRK's $3.66-$3.76 range on...

Overcoming charges related to recalls, Johnson & Johnson (NYSE:JNJ) on Tuesday reported a better-than-expected 23% decline in first-quarter profits...

One of the more closely watched sagas in the pharma biz these days is the dispute between Merck (MRK) and Johnson & Johnson (over a pair of...

Johnson & Johnson's (JNJ) fourth-quarter 2010 earnings (excluding special items) of $1.03 per share was in-line with the Zacks Consensus Estimate...

The closely watched dispute between Merck (MRK) and Johnson & Johnson (JNJ) over a pair of register-ringing rheumatoid arthritis drugs has been...

WASHINGTON (Reuters) - Blockbuster prescription drugs used to treat rheumatoid arthritis and other conditions can increase the risk of potentially deadly cancer in children and teenagers, U.S. health regulators said on Tuesday in ordering stronger warnings on such medications.The Food and ...

FDA clears Johnson & Johnson's successor to the blockbuster arthritis drug RemicadeThe Food and Drug Administration on Friday approved a potential blockbuster drug from Johnson & Johnson that fights three forms of arthritis caused by immune-system disorders.The injectable medication called Simponi is essentially a follow-up to the multibillion-dollar drug Remicade, which is marketed in the U.S. by J& J and Schering have touted ...